GlassScriptPhysician profile
Amira N Ayad
NPI 1417150715
$359,877.56
in general payments reported to CMS, 2019-2025
44 companies · $82K in 2025
The $82K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $274 · 2021: $24K · 2022: $82K · 2023: $69K · 2024: $102K · 2025: $82K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $119K · Consulting Fee: $83K · Travel and Lodging: $41K · Food and Beverage: $9,788 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $119,171.91 |
| Consulting Fee | $82,600.00 |
| Travel and Lodging | $41,119.78 |
| Food and Beverage | $9,787.71 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $269,691.66 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $82,924.35 | 2022-2025 | Trintellix |
| Lilly USA, LLC | $1,348.50 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Currax Pharmaceuticals LLC | $832.75 | 2019-2025 | Contrave, Nexletol, Nexlizet |
| Abbvie INC. | $759.92 | 2021-2025 | Qulipta, Ubrelvy, Synthroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $588.65 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $283.22 | 2021-2025 | |
| Vivus LLC | $276.48 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $236.06 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $231.25 | 2023-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.77 | 2023-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $180.37 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Ironwood Pharmaceuticals, INC | $172.03 | 2022-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $167.69 | 2024-2025 | Voquezna |
| Abbott Laboratories | $151.13 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $149.28 | 2022-2025 | Verquvo, Belsomra, Gardasil 9 |
| Ethicon US, LLC | $144.09 | 2019 | |
| Daiichi Sankyo INC. | $128.69 | 2023-2025 | Injectafer |
| Amarin Pharma, INC. | $112.44 | 2019-2023 | |
| Exact Sciences Corporation | $102.27 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dynavax Technologies Corporation | $92.80 | 2022-2024 | Heplisav-B |
| Bausch Health US, LLC | $91.26 | 2025 | Aplenzin, Wellbutrin |
| Scilex Pharmaceuticals INC. | $80.53 | 2023 | Ztlido |
| Otsuka America Pharmaceutical, INC. | $79.38 | 2022-2023 | Rexulti |
| Astellas Pharma US INC | $78.86 | 2023-2024 | Veozah |
| Rhythm Pharmaceuticals, INC. | $65.35 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $65.29 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.04 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $60.26 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $55.76 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $54.14 | 2025 | Zoryve |
| Rxsight INC | $48.28 | 2024 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Supernus Pharmaceuticals, INC. | $46.22 | 2019 | |
| Dexcom, INC. | $41.07 | 2025 | Dexcom G6 Transmitter |
| Ardelyx, INC. | $39.85 | 2025 | Ibsrela |
| Boston Scientific Corporation | $39.59 | 2022 | |
| Corcept Therapeutics | $26.95 | 2022-2025 | Korlym |
| Biohaven Pharmaceuticals, INC. | $26.45 | 2021 | |
| Philips North America LLC | $25.86 | 2024 | (5044) Mcot |
| Electromed, INC. | $24.35 | 2023 | Smartvest |
| Idorsia Pharmaceuticals US INC | $22.07 | 2023 | Quviviq |
| Vertex Pharmaceuticals Incorporated | $21.50 | 2025 | |
| Ascensia Diabetes Care US INC. | $21.49 | 2024 | |
| Allergan, INC. | $12.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amira Ayad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.